Supplementary Figure 6 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529642.v1

2023-01-01

Abstract:PDF file 154K, Recurrent mTOR mutations mapped onto the crystal structure of mTOR

What problem does this paper attempt to address?

Supplementary Figure 1 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529657.v1

2023-01-01

Abstract:PDF file 85K, mTOR pathway mutations
Supplementary Figure 4 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529648

2023-01-01

Abstract:PDF file 143K, mTOR mutants alter Deptor binding and nutrient deprivation, but not sensitivity to mTOR inhibitors
Supplementary Figure 3 from A Diverse Array of Cancer-Associated mtor Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529651.v1

2023-01-01

Abstract:PDF file 94K,Non-recurrent MTOR mutations confer different degrees of mTORC1 activation
Supplementary Figure 2 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529654

2023-01-01

Abstract:PDF file 106K, S2215Y mTOR activates mTORC1 signaling similar to WT and mutant PI3K-p110alpha
Supplementary Figure 5 from A Diverse Array of Cancer-Associated mtor Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529645.v1

2023-01-01

Abstract:PDF file 73K, mTOR R1208C, V2006L, R2152C, and R2430M fail to confer increased S6K1 phosphorylation
Supplementary Table 1 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529636

2023-01-01

Abstract:XLSX file 89K, All mutations from the cBIO and COSMIC databases in mTOR pathway genes, excluding MTOR, are listed
Supplementary Table 2 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529633.v1

2023-01-01

Abstract:XLSX file 31K, All MTOR mutations from a literature search and the cBIO, COSMIC, and ICGC databases are listed
Supplementary Table 3 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529630.v1

2023-01-01

Abstract:XLSX file 10K, Homologous mutations from S. pombe tor2 in H. sapiens MTOR are listed
Supplementary Table 4 from A Diverse Array of Cancer-Associated mtor Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529627.v1

2023-01-01

Abstract:XLSX file 12K, All activating MTOR mutations from this study are listed
Supplementary Table 2 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529633

2023-01-01

Abstract:XLSX file 31K, All MTOR mutations from a literature search and the cBIO, COSMIC, and ICGC databases are listed
Supplementary Table 5 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529624

2023-01-01

Abstract:XLSX file 17K, All site-directed mutagenesis primers to generate mutant mTOR and Rheb1 are listed
A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity.

Brian C Grabiner,Valentina Nardi,Kıvanc Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H Beck,David M Sabatini

DOI: https://doi.org/10.1158/2159-8290.cd-13-0929

IF: 28.2

2014-01-01

Cancer Discovery

Abstract:Genes encoding components of the PI3K-AKT-mTOR signaling axis are frequently mutated in cancer, but few mutations have been characterized in MTOR, the gene encoding the mTOR kinase. Using publicly available tumor genome sequencing data, we generated a comprehensive catalog of mTOR pathway mutations in cancer, identifying 33 MTOR mutations that confer pathway hyperactivation. The mutations cluster in six distinct regions in the C-terminal half of mTOR and occur in multiple cancer types, with one cluster particularly prominent in kidney cancer. The activating mutations do not affect mTOR complex assembly, but a subset reduces binding to the mTOR inhibitor DEPTOR. mTOR complex 1 (mTORC1) signaling in cells expressing various activating mutations remains sensitive to pharmacologic mTOR inhibition, but is partially resistant to nutrient deprivation. Finally, cancer cell lines with hyperactivating MTOR mutations display heightened sensitivity to rapamycin both in culture and in vivo xenografts, suggesting that such mutations confer mTOR pathway dependency.
Supplementary Figure and Table Legends from A Diverse Array of Cancer-Associated mtor Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529639

2023-01-01

Abstract:PDF file 82K, Supplementary Figure and Table Legends
Supplementary Figure 3 from Mtor Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor Angiogenesis

Debasmita Roy,Sang‐Hoon Sin,Amy Lucas,Raman Venkataramanan,Ling Wang,Anthony Eason,Veenadhari Chavakula,Isaac B. Hilton,Kristen M. Tamburro,Blossom Damania,Dirk P. Dittmer

DOI: https://doi.org/10.1158/0008-5472.22398716.v1

2023-01-01

Abstract:PDF file - 102K, Suppl. Figure 3: Reversibility of rapamycin-induced tumor inhibition in vivo supports a tumor static mechanism of action.
Supplementary Figure 1 from Mtor Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor Angiogenesis

Debasmita Roy,Sang‐Hoon Sin,Amy Lucas,Raman Venkataramanan,Ling Wang,Anthony Eason,Veenadhari Chavakula,Isaac B. Hilton,Kristen M. Tamburro,Blossom Damania,Dirk P. Dittmer

DOI: https://doi.org/10.1158/0008-5472.22398722.v1

2023-01-01

Abstract:PDF file - 41K, Suppl. Figure 1: Inhibition of VEGF secretion of PEL cells by rapamycin as measured by ELISA and bioassay.
Supplementary Figures 1 - 11, Tables 1 - 2 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from Mtor Inhibitor Therapy

Martin H. Voss,A. Ari Hakimi,Can G. Pham,A. Rose Brannon,Ying-Bei Chen,Luı́s Cunha,Oğuz Akın,Han Liu,Shugaku Takeda,Sasinya N. Scott,Nicholas D. Socci,Agnès Viale,Nikolaus Schultz,Chris Sander,Victor E. Reuter,Paul Russo,Emily H. Cheng,Robert J. Motzer,Michael F. Berger,James J. Hsieh

DOI: https://doi.org/10.1158/1078-0432.22450620

2023-01-01

Abstract:PDF file - 3248K, Supplementary Table S1. Histopathologic findings for multi-region analysis. Supplementary Table S2.IMPACT gene list and their respective chromosomal positions. Supplementary Table S5. WEC run statistics on patients #4 and #5. Supplementary Table S6.List of all non-variant mutations detected by IMPACT assays in individual patient samples. Supplementary Table S7. Non-variant mutations identified by WEC in patients #4 and #5. Supplementary Figure 1. Flow chart depicts the IMPACT assay mutation identification and filtering algorithm. Supplementary Figure 2. Flow chart depicts the WEC assay mutation identification and filtering algorithm. Supplementary Figure 3. Sanger validations of mutations in the targeted pathway indentified by IMPACT assay for R1 of patients #1,#2, and #3. Supplementary Figure 4. Sanger validations of mutations in the targeted pathway indentified by IMPACT assay for additional regions analyzed for patients #1, and #3. Supplementary Figure 5. The Q2223K mTOR mutation provokes hyperactivation of mTORC1 in serum free growth conditions. Supplementary Figure 6. Hyperactivation of mTORC1 induced by Q2223K is sensitive to rapalog-based mTOR inhibition. Supplementary Figure 7. Immunoblots detecting phosphorylated mTOR at serine residues 2448 (S2448) and 2481 (S2481). Supplementary Figure 8. Copy number plots for multiple tumor regions in patient #3 showing the loss of chromosome 9 only in tumor regions carrying the TSC1 nonsense mutation (R3, R4). Supplementary Figure 9. Copy number plots for patient with tuberous sclerosis complex and metastatic unclassified RCC with extended benefit from everolimus therapy (44+ months). Supplementary Figure 10. PI3K pathway alterations as reported across 418 cases of clear cell RCC in TCGA. Alterations are detected in 42% of cases. Supplementary Figure 11: Hematoxylin and eosin (H&E) stains and immunohistochemistry for 4EBP1 phosphorylation (Thr 37/46), an mTORC1 downstream effector, in primary kidney tumors and adjacent normal kidney tissue for patients 1-5.
Supplementary Figure S2 from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xiaowen Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chi,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461794

2023-01-01

Abstract:Supplementary Figure S2. Overall survival of melanoma patients in relation to mTOR nonsynonymous mutations.
Supplementary Data from mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK

Hongguang Wu,Dan He,Soma Biswas,Md Shafiquzzaman,Xin Zhou,Jean Charron,Yibin Wang,Bijaya K. Nayak,Samy L. Habib,Huijuan Liu,Baojie Li

DOI: https://doi.org/10.1158/0008-5472.22429198

2023-01-01

Abstract:Supplementary Figures
Supplementary Table S6 from Analysis of mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xianliang Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chen,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461785

2023-01-01

Abstract:Supplementary Table S6. Statistical analysis of the effects of PI3K-AKT-mTOR inhibitors on proliferation of HEK293T cells bearing mTOR mutation.
Supplementary Figure S1 from Analysis of mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xianliang Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chen,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461797.v1

2023-01-01

Abstract:Supplementary Figure S1. Typical staining results of immunohistochemistry.

Supplementary Figure 6 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 1 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 4 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 3 from A Diverse Array of Cancer-Associated <i>mtor</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 2 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 5 from A Diverse Array of Cancer-Associated <i>mtor</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 1 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 2 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 3 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 4 from A Diverse Array of Cancer-Associated <i>mtor</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 2 from A Diverse Array of Cancer-Associated <i>MTOR</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 5 from A Diverse Array of Cancer-Associated <i>MTOR</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity.

Supplementary Figure and Table Legends from A Diverse Array of Cancer-Associated <i>mtor</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 3 from Mtor Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor Angiogenesis

Supplementary Figure 1 from Mtor Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor Angiogenesis

Supplementary Figures 1 - 11, Tables 1 - 2 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from Mtor Inhibitor Therapy

Supplementary Figure S2 from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Data from mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK

Supplementary Table S6 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure S1 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure 6 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 1 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 4 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 3 from A Diverse Array of Cancer-Associated &lt;i&gt;mtor&lt;/i&gt; Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 2 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 5 from A Diverse Array of Cancer-Associated &lt;i&gt;mtor&lt;/i&gt; Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 1 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 2 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 3 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 4 from A Diverse Array of Cancer-Associated &lt;i&gt;mtor&lt;/i&gt; Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 2 from A Diverse Array of Cancer-Associated <i>MTOR</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 5 from A Diverse Array of Cancer-Associated &lt;i&gt;MTOR&lt;/i&gt; Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity.

Supplementary Figure and Table Legends from A Diverse Array of Cancer-Associated &lt;i&gt;mtor&lt;/i&gt; Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 3 from Mtor Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor Angiogenesis

Supplementary Figure 1 from Mtor Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor Angiogenesis

Supplementary Figures 1 - 11, Tables 1 - 2 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from Mtor Inhibitor Therapy

Supplementary Figure S2 from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Data from mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK

Supplementary Table S6 from Analysis of &lt;i&gt;mtor&lt;/i&gt; Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure S1 from Analysis of &lt;i&gt;mtor&lt;/i&gt; Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure 3 from A Diverse Array of Cancer-Associated <i>mtor</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 5 from A Diverse Array of Cancer-Associated <i>mtor</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 4 from A Diverse Array of Cancer-Associated <i>mtor</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 5 from A Diverse Array of Cancer-Associated <i>MTOR</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure and Table Legends from A Diverse Array of Cancer-Associated <i>mtor</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table S6 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure S1 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors